Spero Therapeutics Inc (SPRO)
1.18
-0.07
(-5.60%)
USD |
NASDAQ |
Nov 15, 16:00
1.175
0.00 (0.00%)
After-Hours: 20:00
Spero Therapeutics Research and Development Expense (TTM): 74.01M for June 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 74.01M |
| March 31, 2024 | 59.79M |
| December 31, 2023 | 51.44M |
| September 30, 2023 | 49.97M |
| June 30, 2023 | 40.94M |
| March 31, 2023 | 39.60M |
| December 31, 2022 | 47.59M |
| September 30, 2022 | 49.73M |
| June 30, 2022 | 56.80M |
| March 31, 2022 | 63.09M |
| December 31, 2021 | 64.53M |
| September 30, 2021 | 60.51M |
| June 30, 2021 | 63.78M |
| March 31, 2021 | 64.97M |
| December 31, 2020 | 67.00M |
| Date | Value |
|---|---|
| September 30, 2020 | 79.53M |
| June 30, 2020 | 80.32M |
| March 31, 2020 | 76.68M |
| December 31, 2019 | 65.78M |
| September 30, 2019 | 49.17M |
| June 30, 2019 | 39.14M |
| March 31, 2019 | 34.49M |
| December 31, 2018 | 33.88M |
| September 30, 2018 | 37.26M |
| June 30, 2018 | 35.71M |
| March 31, 2018 | 35.80M |
| December 31, 2017 | 32.87M |
| September 30, 2017 | 27.29M |
| June 30, 2017 | 26.39M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
39.60M
Minimum
Mar 2023
80.32M
Maximum
Jun 2020
60.84M
Average
63.09M
Median
Mar 2022
Research and Development Expense (TTM) Benchmarks
| Arbutus Biopharma Corp | 62.79M |
| Equillium Inc | 38.71M |
| NovaBay Pharmaceuticals Inc | 0.064M |
| Palatin Technologies Inc | 22.40M |
| iBio Inc | 5.185M |